BioSight
Companies
Aktis Oncology, Inc. logo

AKTS

NASDAQBOSTON, MA
Aktis Oncology, Inc.

Aktis Oncology is a clinical-stage oncology company developing targeted radiopharmaceuticals—drugs that deliver radioactive isotopes directly to tumors—using a proprietary miniprotein platform technology designed to treat a broader range of cancers than existing therapies. The company's approach aims to improve tumor targeting, increase time the drug stays in tumors, and reduce radiation exposure to healthy tissue compared to current peptide-based radioconjugate treatments. Aktis is also building internal manufacturing and supply capabilities to support commercialization across multiple cancer types and indications.

Price history not yet available for AKTS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar